A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Public ClinicalTrials.gov record NCT05211895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Study identification
- NCT ID
- NCT05211895
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 791 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2022 (Actual)
- Primary completion
- Aug 10, 2026 (Actual)
- Completion
- Sep 8, 2027 (Estimated)
- Last update posted
- Aug 28, 2026
2022 – 2027
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | Washington D.C. | District of Columbia | 20016 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Saint Augustine | Florida | 32086 | — |
| Research Site | Macon | Georgia | 31217 | — |
| Research Site | Elmhurst | Illinois | 60126 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Ann Arbor | Michigan | 48106-0995 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Reno | Nevada | 89511 | — |
| Research Site | East Brunswick | New Jersey | 08816 | — |
| Research Site | Columbus | Ohio | 43214 | — |
| Research Site | Maumee | Ohio | 43537 | — |
| Research Site | Oklahoma City | Oklahoma | 73102 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Charleston | South Carolina | 29401 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Fort Sam Houston | Texas | 78234 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Fort Belvoir | Virginia | 22060 | — |
| Research Site | Spokane Valley | Washington | 99216 | — |
| Research Site | Appleton | Wisconsin | 54911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 194 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05211895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05211895 live on ClinicalTrials.gov.